Modulation of Neurological Deficits and Expression of Glutamate Receptors during Experimental Autoimmune Encephalomyelitis after Treatment with Selected Antagonists of Glutamate Receptors

Table 1

Characterization of the EAE animal model and clinical parameters in rats with EAE and after treatment with antagonists of glutamate receptors.

	EAE	Amantadine	Memantine	LY 367385	MPEP
Animals with clinical sings (%)	96.2	100	100	100	100
Animals with severe EAE (%)	73.9	62.7*	63.6*	73.6	70.0
Lethality (%)	8.8	0	8.3	0	0
Inductive phase (days)	10.6±2.4	12.1±1.3^∗	12.2±2.1^∗	10.8±1.4	10.5±1.5
Maximal CI (score)	4.5±0.3	2.4±0.4^∗	2.6±0.6^∗	4.1±0.6	3.9±0.5
Cumulative CI (score)	28.6±4.7	19.6±1.6^∗	20.1±2.4^∗	26.98±0.5	27.6±0.7
Duration of disease (days)	21.4±1.8	18.6±1.6^∗	17.8±2.1^∗	20.98±1.9	20.2±1.2
Number of animals	160	24	24	24	24

The values represent the means ± SD. *𝑃<0.05, significantly different when compared with rats with EAE.